Abnormal β-catenin and reduced axin expression are associated with poor differentiation and progression in non-small cell lung cancer

American Journal of Clinical Pathology

Volumn 125, Issue 4, 2006, Pages 534-541

  Xu, Hong Tao ^a   Wang, Liang ^a   Lin, Dong ^a   Liu, Yang ^a   Liu, Nan ^a   Yuan, Xi Ming ^b   Wang, En Hua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Axin; Immunohistochemistry; Lung cancer; WNT signaling; catenin

Indexed keywords

AXIN; BETA CATENIN; WNT PROTEIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CELL DIFFERENTIATION; CLINICAL FEATURE; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 33645547718     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/0MDY02KHEW1F6RT6     Document Type: Article

References (30)

1. Van Aken E, De Wever O, Correia da Rocha AS, et al. Defective E-cadherin/catenin complexes in human cancer. Virchows Arch. 1998;439:725-751.
2. Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol. 2003;129:199-221.
3. Ueta T, Ikeguchi M, Hirooka Y, et al. β-Catenin and cyclin D1 expression in human hepatocellular carcinoma. Oncol Rep. 2002;9:1197-1203.
4. Gerstein AV, Almeida TA, Zhao G, et al. APC/CTNNB1 (β-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer. 2002;34:9-16.
5. Ashihara K, Saito T, Mizumoto H, et al. Mutation of β-catenin gene in endometrial cancer but not in associated hyperplasia. Med Electron Microsc. 2002;35:9-15.
6. Ishizaki Y, Ikeda S, Fujimori M, et al. Immunohistochemical analysis and mutational analyses of beta-catenin, axin family and APC genes in hepatocellular carcinomas. Int J Oncol. 2004;24:1077-1083.
7. Jin LH, Shao QJ, Luo W, et al. Detection of point mutations of the axin1 gene in colorectal cancers. Int J Cancer. 2003;107:696-699.
8. Koppert LB, van der Velden AW, van de Wetering M, et al. Frequent loss of the AXIN1 locus but absence of AXIN1 gene mutations in adenocarcinomas of the gastrooesophageal junction with nuclear β-catenin expression. Br J Cancer. 2004;90:892-899.
9. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004. World Health Organization Classification of Tumours.
10. Watanabe Y. TNM classification for lung cancer. Ann Thorac Cardiovasc Surg. 2003;9:343-350.
11. Pirinen RT, Hirvikoski P, Johansson RT, et al. Reduced expression of α-catenin, β-catenin, and γ-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer. J Clin Pathol. 2001;54:391-395.
12. Nakajima M, Fukuchi M, Miyazaki T, et al. Reduced expression of axin correlates with tumour progression of oesophageal squamous cell carcinoma. Br J Cancer. 2003;88:1734-1739.
13. Zhang Z, Yuan XM, Li LH, et al. Transdifferentiation in neoplastic development and its pathological implication. Histol Histopathol. 2001;16:1249-1262.
14. Luo W, Lin SC. Axin: a master scaffold for multiple signaling pathways. Neurosignals. 2004;13:99-113.
15. Cliffe A, Hamada F, Bienz M. A role of dishevelled in relocating axin to the plasma membrane during wingless signaling. Curr Biol. 2003;13:960-966.
16. Uematsu K, He B, You L, et al. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene. 2003;22:7218-7221.
17. Baeza N, Masuoka J, Kleihues P, et al. AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene. 2003;22:632-636.
18. Su TH, Chang JG, Yeh KT, et al. Mutation analysis of CTNNB1 (beta-catenin) and AXIN1, the components of Wnt pathway, in cervical carcinomas. Oncol Rep. 2003;10:1195-1200.
19. Yeh KT, Chang JG, Lin TH, et al. Correlation between protein expression and epigenetic and mutation changes of Wnt pathway-related genes in oral cancer. Int J Oncol. 2003;23:1001-1007.
20. Lin D, Wang EH, Zhang ZK, et al. Expression of phospho-β-catenin and its significance in non-small cell lung cancer [in Chinese]. Zhonghua Bing Li Xue Za Zhi. 2003;32:54-55.
21. El-Bahrawy M, Poulsom R, Rowan AJ, et al. Characterization of the E-cadherin/catenin complex in colorectal carcinoma cell lines. Int J Exp Pathol. 2004;85:65-74.
22. Cheng XX, Sun Y, Chen XY, et al. Frequent translocalization of β-catenin in gastric cancers and its relevance to tumor progression. Oncol Rep. 2004;11:1201-1207.
23. Imura J, Ichikawa K, Takeda J, et al. β-Catenin expression as a prognostic indicator in cervical adenocarcinoma. Int J Mol Med. 2001;8:353-358.
24. Bismar TA, Humphrey PA, Grignon DJ, et al. Expression of β-catenin in prostatic adenocarcinomas: a comparison with colorectal adenocarcinomas. Am J Clin Pathol. 2004;121:557-563.
25. Sparks AB, Morin PJ, Vogelstein B, et al. Mutational analysis of the APC/β-catenin/Tcf pathway in colorectal cancer. Cancer Res. 1998;58:1130-1134.
26. Clements WM, Wang J, Sarnaik A, et al. β-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res. 2002;62:3503-3506.
27. Shigemitsu K, Sekido Y, Usami N, et al. Genetic alteration of the β-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. Oncogene. 2001;20:4249-4257.
28. Ueda M, Gemmill RM, West J, et al. Mutations of the beta-and gamma-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer. 2001;85:64-68.
29. Cong F, Varmus H. Nuclear-cytoplasmic shuttling of axin regulates subcellular localization of β-catenin. Proc Natl Acad Sci U S A. 2004;101:2882-2887.
30. Wiechens N, Heinle K, Englmeier L, et al. Nucleocytoplasmic shuttling of axin, a negative regulator of the Wnt-beta-catenin pathway. J Biol Chem. 2004;279:5263-5267.